# Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer

> **NCT05032313** · — · COMPLETED · sponsor: **Becton, Dickinson and Company** · enrollment: 371 (actual)

## Conditions studied

- Chronic Lymphoproliferative Diseases (CLPD)

## Interventions

- **DIAGNOSTIC_TEST:** IUO CLPD Limited Panel

## Key facts

- **NCT ID:** NCT05032313
- **Lead sponsor:** Becton, Dickinson and Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-26
- **Primary completion:** 2023-12-29
- **Final completion:** 2023-12-29
- **Target enrollment:** 371 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05032313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05032313, "Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05032313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*